Education
About Us
Working with TipRanks
Follow Us
UCB SA (UCBJY)
OTHER OTC:UCBJY
UCBJY Stock Chart & Stats
$131.75
$1.86(1.89%)
At close: 4:00 PM EST
$131.75
$1.86(1.89%)
Day’s Range― - ―
52-Week Range$71.39 - $150.68
Previous CloseN/A
Volume2.14K
Average Volume (3M)2.85K
Market Cap
$47.47B
Enterprise Value$39.48B
Total Cash (Recent Filing)$2.01B
Total Debt (Recent Filing)$2.88B
Price to Earnings (P/E)32.8
Beta0.48
Next Earnings
Feb 26, 2026EPS Estimate
2.49Last Dividend Ex-Date
Apr 28, 2025Dividend Yield0.59%
Share Statistics
EPS (TTM)2.02
Shares Outstanding389,011,320
10 Day Avg. Volume1,843
30 Day Avg. Volume2,850
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)3.62
Price to Sales (P/S)5.90
P/FCF Ratio39.43
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue5.76
Enterprise Value/Gross Profit7.86
Enterprise Value/Ebitda16.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
UCB SA News
UCBJY FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was $71.39 and its highest was $150.68 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is $47.47B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Feb 26, 2026 which is in 100 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Jul 31, 2025. The company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.927 by $0.093.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Overvalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of $0.79 which represents an annual dividend yield of 0.59%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 2.49.
How many shares outstanding does UCB SA have?
UCB SA has 389,011,320 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of $2.02 in its last earnings report, beating expectations of $1.927. Following the earnings report the stock price went up 2.415%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in UCBJY
UCB SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.69%
12-Months-Change
Fundamentals
Return on Equity
13.80%
Trailing 12-Months
Asset Growth
20.44%
Trailing 12-Months
Company Description
UCB SA
UCB SA is a global biopharmaceutical company based in Belgium, specializing in the development and commercialization of innovative medicines for neurological and immunological disorders. Operating primarily within the healthcare sector, UCB focuses on areas such as epilepsy, Parkinson's disease, Crohn's disease, and rheumatoid arthritis, offering products that address significant unmet medical needs. The company's core offerings include branded pharmaceuticals and biologics, which are designed to improve the quality of life for patients with chronic conditions.
UCBJY Company Deck
UCBJY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a largely positive outlook with UCB showcasing strong revenue growth, successful product launches, and a robust pipeline. However, challenges such as pricing pressures, currency headwinds, and potential tariffs introduce some uncertainties.View all UCBJY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---